J Neuroinflammation. 2016 Sep 27;13(1):280. Jarius S1, Ruprecht K2, Kleiter I3, Borisow N4,5, Asgari N6, Pitarokoili K3, Pache F4,5, Stich O7, Beume LA7, Hümmert MW8,…
Neurotherapeutics. 2016 Jan;13(1):70-83. doi: 10.1007/s13311-015-0400-8. Kleiter I, Gold R. Neuromyelitis optica spectrum disorders (NMOSD) are important evolving entities, which have reached much attention in the…
Optimized Azathioprine Can Be Effective for Neuromyelitis Optica Weight-based dosing, laboratory monitoring for biologic effect, and concurrent use of prednisone are important for treatment success. Azathioprine is often used to prevent relapses in patients with neuromyelitis optica (NMO), but data on its efficacy are limited.
Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Costanzi C , Matiello M , Lucchinetti CF , Weinshenker BG , Pittock SJ , Mandrekar J , Thapa P , McKeon A .
Neuromyelitis optica (NMO, Devic’s disease), an uncommon demyelinating neuro-immunological disease, can be associated with autoimmune diseases. In SLE associated forms anti-aquaporin-4 antibody positivity can help differentiating between SLE nerve system manifestation and NMO.
Neuromyelitis optica (NMO) is a relapsing inflammatory condition characterized by selective involvement of the optic nerves and spinal cord. Humoral immune mechanisms play a role in the pathogenesis of NMO.
OBJECTIVE:To evaluate the efficacy, tolerability, optimal dosing, and monitoring of azathioprine in patients with neuromyelitis optica (NMO). METHODS: This was a chart review and telephone follow-up study of 99 patients with NMO spectrum of disorders (NMOSD) treated with azathioprine (1994-2009). NMOSD were NMO (2006 diagnostic criteria) or partial NMO forms (NMO-immunoglobulin G seropositive)
Background: Based on case series and anecdotal evidence, immunosuppression has been shown to reduce relapse rates and delay disability in Neuromyelitis Optica spectrum disorders (NMOSD) and is currently the mainstay of disease modifying treatment.
OBJECTIVE: To analyze treatment response in Brazilian patients with neuromyelitis optica. DESIGN: Retrospective review. SETTING: Neuroimmunology Clinic of the Federal University of Sao Paulo, Sao Paulo, Brazil